Monthly Archives: June 2010

Veeda to conduct bulk of $8.4 mn clinical research projects in India

Nearly 60% of its global TO comes from India.

Columbus headquartered Veeda Oncology, a full service Oncology clinical research organisation (CRO) with facilities in North America, Europe and India, plans to conduct the bulk of the recent $8.4 million of new clinical research programs it has been awarded in the last one month in India itself. The awarded work will be conducted in India, Europe and the US. A large part of the clinical trials and data management and biostatistics work would be conducted in India. Matt Bowman, president and CEO of Veeda Oncology, said “”We are enjoying our continued repeat business from our existing clients as well as these five new clients””.

The CRO has invested around Rs75 crore in its Indian operations so far, and employs around 400 people. “”We plan to recruit more people in India,US and Europe””, the company said in an e-mailed response. Veeda Oncology is part of Veeda Group, the largest Phase I CRO in India also engaged in early clinical development and Phase II clinical research since 2005 having 6 offices across India, UK, USA & Europe.

”India currently contributes to over 60 per cent of Veeda’s global turnover, and $64 billion clinical research market is turning towards destinations like India to outsource various functions, Veeda hopes that the Indian CRO industry is likely to show a positive curve in growth graph””, the company informed.

Its Indian operations have grown at the rate of more than 35 per cent per annum for the last five years. By 2012, analysts project that more than 65 per cent of all FDA regulated trials will take place outside the United States.

This is reflected in the Indian biotechnology market, which is expected to grow at a compounded annual growth rate of 30 per cent, and the Indian CRO market, which is expected to see growth of 49 per cent annually.

”Generic Post-
It is time for the world of generics to take a changed approach to the Pharmaceutical industry. The drug industry is moving in a “”generic”” way. All major global pharma are taking the one strong route towards either “”generic”” Acquisitions or generic presence in emerging markets like India. Take the example of Pfizer which a few months got into a licensing strategy with Indian company , Aurobindo Pharma for more the 30 products & Claris life sciences in for off patent injectables & is expected to take a few more positions in the Indian generic space…………………..”

”Torrent and IPCA are relevant and healthy stocks in the longterm

Both companies today are exporting drugs to EU and Torrent sends futher to Brazil via EU.

The recent flurry of events in the EU today are emphasing on generic drugs and UK , Germany, Italy and spain being major players in the same. And Greece which has recently declared drug pricing cuts by 25% which has made many big MNC’s withdraw their drug supplies will put Indian companies which sell cheaper generic drug versions in demand.

For Strides, I would not say much because tehy in a severe financial crisis and have had corporate reorganization at the top level in the last 1 year

They are moving towards S africa as well as Brazil but they are trying to enter the generic drug cancer segment (Risky area but very potential) as well. ( I would keep my fingers crossed on their stock).

Dishman would according to me would be worthwhiwl only a mediocre stock. They have bought over Solvay but that will take some to perform.

Please NOTE: These are only personal opinions and based on daliy news clips and are not intended for any misuse.”

“The recent US healthcare bill will further propel the growth of India’s pharmaceutical industry, which is largely built around generic drug market and contract manufacturing. The bill seeks to reduce the healthcare budget and brings an additional 32 million people into the insurance net.
Pharmaceutical companies in India have leveraged opportunities and their skills in process innovation to achieve growth. They also enjoy the factorial advantage of having access to a good talent pool at affordable costs. The industry today boasts of having the largest number of US Food and Drug Administration (FDA) approved production facilities outside the US. As the industry matures, the growth has to come not only through capacity expansion but also through productivity improvements and achieving operational excellence.
It is time for pharmaceutical companies in India to take the next step of leveraging enabling technologies for improving productivity and gaining sustainable competitiveness. Investments in enabling technologies will have a force multiplier effect on the productivity growth of pharmaceutical companies in India. More importantly, these companies have to protect their well-earned brand image, and this calls for adopting the most appropriate technologies to satisfy regulatory authorities about compliance to standards, good manufacturing practices, electronic record keeping, and such others.”

EU and India are in talks on a free trade agreement that they hope could be completed in October this year.
If the agreement takes its final shape, prices of medicines in India would go up because the bilateral deal would tighten the protection of intellectual property rights of drug-makers and require the manufacturers of generic drugs to make their own drug tests instead of relying on data from the original pharmaceutical firms.
EU Trade Commissioner Karel De Gucht said the EU had agreed to make changes to the deal and that developing countries had the right to access essential medicines. The European Commission is going to take care that there are no hindrances for access to essential medicines for people from a developing country.

Last year saw a wonderful wave of venture cash crashing into biotech coffers. The 2009 yearend numbers were up significantly from 2008, with more deals done (57 vs. 43) and investors shoveling 38 percent more into Series A, plus 36 percent more into Series B rounds.
R&D stage companies got more of the money than clinical stage deals, and original innovation was rewarded more than firms reducing technical risk through in-licensing or reformulation plays.
Sadly, the new decade isn’t following suit as yet. Biotechs raised an anemic $374 million in the first quarter, a 38 percent drop from first quarter 2009. That money flowed into just 22 deals this year, vs. 31 deals this time last year.

After the “”Blockbuster”” approval of the prostrate cancer vaccine, Provenge, the FDA has decided to carry out ”surveillance”” studies on almost all medications used to treat prostrate cancer in men.
Medications primarily used to treat men with prostate cancer, have been associated with a small increased risk for diabetes, heart attack, stroke, and sudden death in men treated with one of the medications. The proof of this is a screen shot from the website which to the surprise of many. Its indeed amazing that the FDA within 2 days of its approval of the novel prostate cancer vaccine has now decided to “”dictate”” safety terms on existing drugs used to treat prostrate cancer.

“Global contract research services firm Charles River Laboratories is expanding its presence in China with the acquisition of WuXi PharmaTech, a major drug research and development outsourcing company with expertise in discovery chemistry and operations in both China and the United States. The $1.6 billion cash and stock deal will expand the global reach and growth opportunities for both companies.
This deal has brought a revolution in the outsourcing market by creating the only global contract research organization, or CRO, to offer fully integrated research and drug development services from molecule creation to first-in-human testing.
Needs to be seen as to how the deal completion would take place as both are listed companies on the NYSE. ”

World cancer Summit in 2008 was marked with the Following:

Cancer prevention and early detection Increase efforts to reduce tobacco consumption by encouraging governments to fully implement and enforce the FCTC (WHO Framework Convention on Tobacco Control) Raise awareness about the need for culturally sensitive cancer risk reduction campaigns, along with public and professional education about cancer warning signs. Push governments to implement policies that will support risk-reducing strategies at a community level and enable individuals to make more informed consumption choices and adopt healthier behavior Encourage governments to implement measures to reduce people’s exposure to environmental and occupational carcinogens Undertake actions to ensure that vaccines and other strategies that are shown to prevent cancer-causing infections are made more widely available Advocate for the provision of affordable screening programmes for which there is evidence of efficacy in the population in question. Undertake pilot projects that are designed to evaluate the feasibility and efficacy in populations in which the screening technology has not yet been tested.

Cancer treatment Promote the development and use of cancer treatment guidelines that are relevant to local needs and resources. Ensure that sufficient treatment, rehabilitation and palliative care facilities and well-trained staff are available to meet the physical, social and emotional needs of patients with cancer Take steps to tackle the many barriers to optimal pain control. Work with governments to address the over-regulation of pain medicines.Cooperate with international organizations, including the International Narcotics Control Board and the World Health Organization, to ensure that global implementation of the UN’s international drug control conventions do not unduly interfere with legitimate efforts to advance access to pain medicines for cancer patients in pain Work with the pharmaceutical industry to increase access to cancer medicines that are affordable and of assured quality Increase the number of health professionals with expertise in all aspects of cancer control by providing specialist training opportunities and fellowships to enable professionals to study in specialist settings Raise awareness about the impact of health worker emigration on the ability of countries to provide adequate levels of cancer care and work collectively to address global and national health workforce shortages and the resultant deepening of inequity Increase investment in independent basic and applied cancer research and accelerate the translation of research findings into clinical and public health practice Encourage cancer research organizations in different countries to collaborate, share data and define complementary research objectives to optimize the use of the limited funds available for cancer research and reduce duplication of effort .

“Half of all adults in the US have one chronic condition associated with an increased risk of cardiovascular disease, according to data from the National Health and Nutrition Examination Survey.
The report, from the Centers for Disease Control and Prevention, showed that 45% of individuals 20 years of age and older have hypercholesterolemia, hypertension, or diabetes. Of these, 3% of adults had all three conditions and 13% had two conditions. Hypertension and hypercholesterolemia were present in 9% of adults, and 3% of adults had high blood pressure and diabetes.
The prevalence of diagnosed or undiagnosed high blood pressure, elevated cholesterol levels, or diabetes varied by ethnicity, with non-Hispanic black individuals more likely than non-Hispanic white and Mexican American individuals to have at least one of these three conditions.
Compared with Mexican Americans, non-Hispanic white individuals were more likely to have only one of these chronic conditions, while non-Hispanic black people were more likely than white individuals and Mexican American individuals, 16.4% vs 12.8% and 12.7%, respectively, to have two comorbid conditions. In total, 4.6% of non-Hispanic black people have hypertension, hypercholesterolemia, and diabetes ”